Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections.

摘要: Emergence and re-emergence of respiratory virus infections represent a significant threat to global public health, as they occur seasonally less frequently (such in the case influenza virus) pandemic infections. Some these viruses have been human population for centuries others had recently emerged health problem. Influenza affecting long time now; however, their ability rapidly evolve through antigenic drift shift causes emergence new strains. A recent example events is avian-origin H7N9 outbreak currently undergoing China. Human are resistant amantadines some strains also neuraminidase inhibitors greatly limiting options treatment. Respiratory syncytial (RSV) may cause lower tract infection characterized by bronchiolitis pneumonia mainly children elderly. Infection with RSV can severe disease even death, imposing burden pediatric geriatric systems worldwide. Treatment supportive since only approved therapy, monoclonal antibody, recommended prophylactic use high-risk patients. The Middle East syndrome coronavirus (MERS-CoV) newly emerging virus. was first recognized 2012 it associated that more patients comorbidities. No licensed vaccines or antivirals yet treatment MERS-CoV humans. It clear discovery development novel be used alone combination existing therapies treat important viral critical. In this review, we will describe therapeutics under